Sign up for news updates

ILCN Lung Cancer News

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

ILCN Lung Cancer News

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

June 2018

Add ILCN as a preferred source
  • Highlights of the 8th Edition of the TNM Staging System: Practicalities and Tools

    Highlights of the 8th Edition of the TNM Staging System: Practicalities and Tools

    Hisao Asamura, et al.
    Evolving Standards of Care

    Editor’s Note: The following was written on behalf of the IASLC Staging and Prognostic Factors Committee. The IASLC Staging and Prognostic Factors Committee (SPFC) proposed revisions to the lung cancer staging system for the 8th edition of the TNM Classification of Malignant Tumors. The Union for International Cancer Control (UICC) and the American Joint Committee…

  • The Lung Master Protocol: Results and Updates

    The Lung Master Protocol: Results and Updates

    Evolving Standards of Care

    By Vassiliki Papadimitrakopoulou, MD Posted: June 2018 The Lung Master Protocol Trial (Lung-MAP) was designed in 2014 as a phase II/III trial overseen by a private–public collaboration among institutions participating in the National Cancer Institute’s (NCI’s) National Clinical Trials Network, the Foundation for the National Institutes of Health (FNIH), patient advocacy organizations, and numerous pharmaceutical…

  • Managing Medication Shortages of Life-Saving Oncologic Therapeutics

    Managing Medication Shortages of Life-Saving Oncologic Therapeutics

    Global Initiatives

    Natural disasters, such as Hurricane Maria, may have contributed to more acute shortages than previously experienced. By Jorge Garcia, PharmD, MS, MHA, MBA, and Dina B. Dumercy, PharmD, BCOP, BCPS Posted: June 2018 Drug shortages in oncology date back to the late 1980s, when there was a scarcity of paclitaxel. Since then, with an increase…

  • The Role for Trimodality Therapy in Stage III NSCLC

    The Role for Trimodality Therapy in Stage III NSCLC

    Radiation Oncology

    By Leah Lawrence Posted: June 2018 The use of trimodality therapy—the combination of chemoradiotherapy followed by surgery—remains controversial for patients with locally advanced cN2-N3 NSCLC. According to the National Comprehensive Cancer Network guidelines, definitive chemoradiation therapy is the standard of care for the majority of patients with stage III NSCLC, and trimodality treatment is used…

  • Exploring Barriers to Combined-Modality Therapy for LS-SCLC

    Exploring Barriers to Combined-Modality Therapy for LS-SCLC

    Evolving Standards of Care

    By Anna Farago, MD, PhD Posted: June 2018 Small cell lung cancer (SCLC) accounts for approximately 15% of all new lung cancer diagnoses in the United States. Approximately 30% of patients with newly diagnosed SCLC have limited-stage (LS) disease based on the Veterans’ Administration Lung Study Group staging system; this means that the radiographically evident…

  • Dr. Howard 'Skip' Burris III Shares His Views on Clinical Trial Eligibility Criteria, Payer Involvement

    Dr. Howard 'Skip' Burris III Shares His Views on Clinical Trial Eligibility Criteria, Payer Involvement

    Uncategorized

    Posted: June 2018 Howard A. “Skip” Burris III, MD, is the chief medical officer and president of clinical operations at Sarah Cannon, the Cancer Institute of HCA Healthcare, where he leads clinical, strategic, and drug-development initiatives. Dr. Burris also is an associate with Tennessee Oncology, PLLC. In the interview below, Dr. Burris discusses the “extended…

  • FDA Fosters Understanding about Approval Process for Biosimilars

    FDA Fosters Understanding about Approval Process for Biosimilars

    Regulatory Agency Perspective

    By Leah Christl, PhD, Associate Director for Therapeutic Biologics and Director of the Therapeutic Biologics and Biosimilars Staff, Center for Drug Evaluation and Research, FDA Posted: June 2018 All FDA-approved biologics, including reference and biosimilar products, undergo a thorough evaluation so that patients can be assured of the efficacy, safety, and quality of these products.…

  • Oncologic Biologic Biosimilars Are Coming to Market: Are You Ready?

    Oncologic Biologic Biosimilars Are Coming to Market: Are You Ready?

    Evolving Standards of Care

    Biosimilars have proven themselves to the U.S. FDA, but clinicians are still wary. By Leah K. Lawrence Posted: June 2018 Healthcare providers are more than familiar with the use of brand name and generic drugs, but the passage of the Biologics Price Competition and Innovation (BPCI) Act of 2009 introduced a new player in the…

View ILCN Archives

Provider Resources

Popular Articles